Related Experiment Videos
Custom chemical microarray production and affinity fingerprinting for the S1 pocket of factor VIIa
Stefan Dickopf1, Michael Frank, Hans-Dieter Junker
1Graffinity Pharmaceuticals AG, Im Neuenheimer Feld 518-519, D-69120 Heidelberg, Germany.
Analytical Biochemistry
|November 3, 2004
Summary
Surface plasmon resonance (SPR) fragment screening identified compounds binding to factor VIIa (FVIIa). This method enables de novo drug discovery and lead development by detecting weak interactions with low molecular weight ligands.
Area of Science:
- Biochemistry
- Chemical Biology
- Drug Discovery
Background:
- Factor VIIa (FVIIa) is a key enzyme in the coagulation cascade.
- Identifying novel inhibitors of FVIIa is crucial for developing anticoagulants.
- Fragment-based screening is a powerful approach for drug discovery.
Purpose of the Study:
- To evaluate surface plasmon resonance (SPR)-based fragment screening for identifying FVIIa binders.
- To explore the utility of chemical microarray technology for fragment screening.
- To discover novel low molecular weight compounds targeting FVIIa.
Main Methods:
- Virtual screening based on pharmacophore models to select potential FVIIa binders.
- Immobilization of selected fragments onto microarrays.
- Affinity fingerprinting using SPR detection to identify specific interactions.
Main Results:
- Identified specific compounds interacting with FVIIa.
- Compounds fell into four distinct structural classes.
- Demonstrated the ability to detect weak interactions with low molecular weight ligands.
Conclusions:
- SPR-based fragment screening on chemical microarrays is applicable for FVIIa inhibitor discovery.
- This technology provides valuable chemobiological information for de novo drug design.
- The platform effectively detects weak interactions, facilitating lead development.